159 related articles for article (PubMed ID: 38604811)
1. Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.
John N; Schlintl V; Sassmann T; Lindenmann J; Fediuk M; Wurm R; Douschan P; Zacharias M; Kalson L; Posch F; Absenger G; Brcic L; Jost PJ; Terbuch A
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604811
[TBL] [Abstract][Full Text] [Related]
2. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
[TBL] [Abstract][Full Text] [Related]
3. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
Ilie M; Long-Mira E; Bence C; Butori C; Lassalle S; Bouhlel L; Fazzalari L; Zahaf K; Lalvée S; Washetine K; Mouroux J; Vénissac N; Poudenx M; Otto J; Sabourin JC; Marquette CH; Hofman V; Hofman P
Ann Oncol; 2016 Jan; 27(1):147-53. PubMed ID: 26483045
[TBL] [Abstract][Full Text] [Related]
5. Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples.
Ilié M; Hofman V; Bontoux C; Goffinet S; Benzaquen J; Heeke S; Boutros J; Lassalle S; Long-Mira E; Zahaf K; Lalvée S; Lespinet-Fabre V; Bordone O; Tanga V; Gómez-Caro A; Cohen C; Berthet JP; Marquette CH; Hofman P
Lung Cancer; 2023 Jul; 181():107230. PubMed ID: 37150140
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence.
Lacour M; Hiltbrunner S; Lee SY; Soltermann A; Rushing EJ; Soldini D; Weder W; Curioni-Fontecedro A
Clin Lung Cancer; 2019 Sep; 20(5):391-396. PubMed ID: 31262689
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
9. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
11. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
15. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study.
Russell PA; Farrall AL; Prabhakaran S; Asadi K; Barrett W; Cooper C; Cooper W; Cotton S; Duhig E; Egan M; Fox S; Godbolt D; Gupta S; Hassan A; Leslie C; Leong T; Moffat D; Qiu MR; Sivasubramaniam V; Skerman J; Snell C; Walsh M; Whale K; Klebe S
Pathology; 2023 Dec; 55(7):922-928. PubMed ID: 37833206
[TBL] [Abstract][Full Text] [Related]
16. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
Kitazono S; Fujiwara Y; Tsuta K; Utsumi H; Kanda S; Horinouchi H; Nokihara H; Yamamoto N; Sasada S; Watanabe S; Asamura H; Tamura T; Ohe Y
Clin Lung Cancer; 2015 Sep; 16(5):385-90. PubMed ID: 25937270
[TBL] [Abstract][Full Text] [Related]
17. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
19. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
20. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]